Intravitreal Sirolimus as Therapeutic Approach to Uveitis
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out about the safety and effectiveness of two different
doses the study drug, sirolimus, administered intravitreally in patients with uveitis. The
potential effectiveness of sirolimus can be utilized to control inflammation in uveitis and
yet avoid the potential complications that are usually associated with the systemic use of
the drug and other immunomodulatory therapies. In this study, the investigators will
administer sirolimus inside the eye (intravitreally) in one of two doses (440mcg/mcL or
880mcg/mcL). Local administration of sirolimus to the eye is not expected to have effects on
the rest of the body. Therefore, it may offer a safer way than the current methods used to
control the inflammation caused by non-infectious uveitis.